Biohaven (BHVN) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biohaven (BHVN) has outperformed Vera Therapeutics (VERA) over the past year, gaining 27.9% versus a loss of 10.6%. Biohaven is the larger company by market cap ($1.87 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | VERA |
|---|---|---|
| Share price | $12.39 | $25.45 |
| Market cap | $1.87B | $1.84B |
| 1-day change | -9.23% | -4.86% |
| YTD return | +9.74% | -49.74% |
| 1-year return | +27.86% | -10.58% |
| 5-year return | — | -15.17% |
| EPS (TTM) | $-3.77 | $-5.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | $-299.62M |
| 52-week high | $18.24 | $56.05 |
| 52-week low | $8.03 | $25.08 |
| Distance from 52-week high | -32.07% | -54.59% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +102.82% | +180.39% |
| Average volume | 3.24M | 1.95M |
| Shares outstanding | 151.06M | 72.30M |
| Employees | 274 | 362 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHVN has outperformed VERA by 38.4 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees
BHVN vs VERA FAQ
Which is bigger, Biohaven or Vera Therapeutics?
Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.84B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, BHVN or VERA?
BHVN returned +27.86% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.